The stock has a 36-month beta value of 2.90. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for ATHA is 35.48M, and at present, short sellers hold a 4.64% of that float. On September 27, 2024, the average trading volume of ATHA was 734.68K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ATHA) stock’s latest price update
Athira Pharma Inc (NASDAQ: ATHA)’s stock price has decreased by -4.19 compared to its previous closing price of 0.44. However, the company has seen a -9.96% decrease in its stock price over the last five trading sessions. proactiveinvestors.com reported 2024-09-19 that ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has expanded its Angilak Project in Nunavut by acquiring the entire Lac 50 structural corridor, along with an additional prospective parallel corridor. Both corridors are linked to the Snowbird Tectonic Zone, a significant crustal structure that extends from the Athabasca Basin to the Angikuni Basin.
ATHA’s Market Performance
Athira Pharma Inc (ATHA) has seen a -9.96% fall in stock performance for the week, with a -87.32% decline in the past month and a -84.14% plunge in the past quarter. The volatility ratio for the week is 8.38%, and the volatility levels for the past 30 days are at 9.08% for ATHA. The simple moving average for the last 20 days is -58.47% for ATHA stock, with a simple moving average of -84.03% for the last 200 days.
Analysts’ Opinion of ATHA
Many brokerage firms have already submitted their reports for ATHA stocks, with Mizuho repeating the rating for ATHA by listing it as a “Neutral.” The predicted price for ATHA in the upcoming period, according to Mizuho is $0.50 based on the research report published on September 19, 2024 of the current year 2024.
ATHA Trading at -81.96% from the 50-Day Moving Average
After a stumble in the market that brought ATHA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.26% of loss for the given period.
Volatility was left at 9.08%, however, over the last 30 days, the volatility rate increased by 8.38%, as shares sank -87.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -87.69% lower at present.
During the last 5 trading sessions, ATHA fell by -9.96%, which changed the moving average for the period of 200-days by -78.75% in comparison to the 20-day moving average, which settled at $0.8644. In addition, Athira Pharma Inc saw -82.77% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATHA starting from Mark James Litton, who proposed sale 5,032 shares at the price of $0.00 back on Sep 05 ’24. After this action, Mark James Litton now owns shares of Athira Pharma Inc, valued at $1 using the latest closing price.
Gengos Andrew, the CFO and Chief Business Officer of Athira Pharma Inc, sale 1,272 shares at $0.57 during a trade that took place back on Sep 05 ’24, which means that Gengos Andrew is holding 97,532 shares at $720 based on the most recent closing price.
Stock Fundamentals for ATHA
Current profitability levels for the company are sitting at:
- -73.31 for the present operating margin
- 0.41 for the gross margin
The net margin for Athira Pharma Inc stands at -68.51. The total capital return value is set at -1.44. Equity return is now at value -84.57, with -71.06 for asset returns.
Based on Athira Pharma Inc (ATHA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -69.94. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -62.26.
Currently, EBITDA for the company is -126.12 million with net debt to EBITDA at 0.67. When we switch over and look at the enterprise to sales, we see a ratio of -39.07. The receivables turnover for the company is 1.02for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.97.
Conclusion
To sum up, Athira Pharma Inc (ATHA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
